NCT06349239 2024-04-05
ORAZ-351
Centre Hospitalier Universitaire de Nice
Unknown
Clinical Trials
251 trialsNCT04470947 2024-03-22
EXALT-2
Medical University of Vienna
Unknown
NCT03560882 2024-03-21
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
University of Kansas Medical Center
Phase 1 Unknown
NCT03291444 2024-03-15
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Zhujiang Hospital
Phase 1 Unknown
NCT06285136 2024-02-29
Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult
The Second Affiliated Hospital of Kunming Medical University
Phase 2/3 Unknown
NCT04330820 2024-02-28
RELAX
Technische Universität Dresden
Phase 1/2 Unknown
NCT04090268 2024-01-02
SportTherapy
University of Milano Bicocca
Phase NA Unknown
NCT06162325 2023-12-08
Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients
Peking Union Medical College Hospital
Unknown
NCT05583175 2023-11-28
Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT05918198 2023-11-21
Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Peking University People's Hospital
Phase 2 Unknown
NCT06141304 2023-11-21
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
The First Hospital of Jilin University
Phase 2 Unknown
NCT06073730 2023-10-10
Viale-a
The Second Affiliated Hospital of Kunming Medical University
Phase 3 Unknown
NCT04888741 2023-09-28
MoTD
University of Birmingham
Phase 2 Unknown
NCT05982756 2023-08-09
Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML
Zhongnan Hospital
Phase 1 Unknown
NCT05005299 2023-08-01
VICTORY
Melbourne Health
Phase 1 Unknown
NCT05951855 2023-07-19
Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05949762 2023-07-18
Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly
The Second Affiliated Hospital of Kunming Medical University
Phase 1/2 Unknown
NCT04923919 2023-07-13
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Unknown
NCT05919199 2023-06-26
FDG-PETAML
First Affiliated Hospital of Jinan University
Unknown
NCT05893472 2023-06-08
A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.
The Second Affiliated Hospital of Kunming Medical University
Phase 1/2 Unknown
NCT05264883 2023-05-30
Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Unknown
NCT05140811 2023-05-24
A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2 Unknown
NCT04217278 2023-05-10
COSI
University of Birmingham
Phase 2/3 Unknown
NCT05805072 2023-05-06
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT05823714 2023-04-21
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05697510 2023-04-06
SILTUXILAM
Nantes University Hospital
Phase 1 Unknown
NCT05791890 2023-03-30
GilteRInf
University of Rome Tor Vergata
Unknown
NCT02931942 2023-03-16
Changing Over Time of Ascorbic Acid After Chemotherapy
Maastricht University Medical Center
Unknown
NCT03846362 2023-03-16
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Unknown
NCT05312112 2023-03-02
Real World Outcomes Using Novel Agents for AML in the UK
Guy's and St Thomas' NHS Foundation Trust
Unknown
NCT05744440 2023-02-27
Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT
Xuzhou Medical University
Phase EARLY_PHASE1 Unknown
NCT05665075 2023-01-03
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
Zhejiang University
Phase 1 Unknown
NCT05665114 2023-01-03
Natural Killer(NK) Cell Therapy in r/r AML
Zhejiang University
Phase 1 Unknown
NCT05654194 2022-12-16
Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT05519384 2022-11-28
Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Unknown
NCT04913922 2022-11-08
AARON
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT03855371 2022-11-04
PANDA-T0
Ruijin Hospital
Phase 1 Unknown
NCT05596968 2022-10-27
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
Nanfang Hospital, Southern Medical University
Unknown
NCT05596981 2022-10-27
The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
Nanfang Hospital, Southern Medical University
Unknown
NCT05587088 2022-10-19
PA001
Hospital Universitario San Ignacio
Phase 1/2 Unknown
NCT05577611 2022-10-13
An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Zhongnan Hospital
Phase 1 Unknown
NCT03825367 2022-10-12
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Unknown
NCT04226768 2022-10-04
Enhanced Palliative Care in MDS and AML
The University of Hong Kong
Phase NA Unknown
NCT04689815 2022-10-04
Oral Arsenic Trioxide for NPM1-mutated AML
The University of Hong Kong
Phase 2 Unknown
NCT04248595 2022-09-08
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
Zhongda Hospital
Phase 2 Unknown
NCT04687761 2022-09-08
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
PETHEMA Foundation
Phase 1/2 Unknown
NCT05512104 2022-08-23
Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression
Assiut University
Unknown
NCT05488132 2022-08-04
Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Xuzhou Medical University
Phase 1/2 Unknown
NCT03173612 2022-08-03
The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Unknown
NCT05457361 2022-07-14
VAH Versus VA for Salvage Therapy of R/R-AML
Nanfang Hospital, Southern Medical University
Phase 3 Unknown